Lanicemine
As of the edition of 20 October 2026, Lanicemine is a small molecule: went quiet in 2019; acts on GRIN1, GRIN2A and GRIN2B and 4 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2019
- Kind
- Small molecule
- Registered trials
- 10, 2 stopped early
- Disease areas
- Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product5 company-target rows are on route A because of Lanicemine.
See the 5 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| GRIN2D | Glutamate receptor ionotropic, NMDA 2D | O15399 |
| GRIN3B | Glutamate receptor ionotropic, NMDA 3B | O60391 |
| GRIN1 | Glutamate receptor ionotropic, NMDA 1 | Q05586 |
| GRIN2A | Glutamate receptor ionotropic, NMDA 2A | Q12879 |
| GRIN2B | Glutamate receptor ionotropic, NMDA 2B | Q13224 |
| GRIN2C | Glutamate receptor ionotropic, NMDA 2C | Q14957 |
| GRIN3A | Glutamate receptor ionotropic, NMDA 3A | Q8TCU5 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 6 | 4 | 0 | 2 |
| Phase 2 | 4 | 4 | 0 | 0 |
| All trials | 10 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Lead sponsor of trials | 2007 to now |